Mayaro virus (MAYV) is a positive-sense single stranded RNA virus that belongs to the genus Alphavirus, a member of the Togaviridae family of viruses. It is a member of the Semliki Forest antigenic sero-complex, a serological group within the Alphavirus genus, and is closely related to Chickungunya virus (CHIKV) (Esposito, D.L.A).
MAYV is an arthropod-borne virus that is thought to be transmitted by Haemagogus mosquitoes to forest dwelling non-human primates and migratory birds, which act as reservoirs for the virus. Humans can be infected when working or living in forest areas where MAYV is prevalent. Studies suggest that MAYV may be also transmitted by the Aedes aegypti mosquito, raising concerns that the virus could spread to urban areas where A. aegypti are widespread.
In humans, Mayaro virus causes an acute febrile illness which presents with a range of non-specific clinical symptoms including headache, myalgia, rash, diarrhoea, nausea and severe persistent joint pain, which are similar to symptoms of Dengue fever and Chikungunya. Since it was first isolated in Trinidad in 1954, MAYV has caused major outbreaks in some rural areas of Brazil and sporadic cases in Central and South American countries. However, reports suggest that cases of MAYV infection may be higher than previously documented owing to similarities that exist between symptoms of Mayaro fever, Dengue fever, Chikungunya and other febrile tropical diseases (CDC).
MAYV is recognised as an emerging virus with the potential to cause a major epidemic in Central and South American countries. Currently, there is no licensed prophylactic vaccine or specific treatment for MAYV fever. Prevention of MAYV is through vector control measures to reduce transmission of the virus. Given the geographical distribution of MAYV and the similarity of the symptoms of Mayaro fever to infections caused by other arboviruses such Dengue fever, Chikungunya and Zika virus, it is considered important to be able to differentiate diagnostically between these arboviral diseases (CDC). Diagnosis of MAYV infection may be achieved by serological testing for MAYV specific IgM antibodies using enzyme immunoassays (EIA). However, cross reactivity with related viruses can reduce assay sensitivity and prevent accurate diagnosis (Figueiredo, ML).
The Native Antigen Company (NAC) specialises in development and manufacture of native and recombinant viral antigens. Our recombinant Mayaro virus antigens will assist researchers and assay developers in preparing improved tests to detect Mayaro infection.
1. Esposito DLA and Fonseca BALD (2017). Will Mayaro virus be responsible for the next outbreak of an arthropod-borne virus in Brazil? Braz J Infect Dis.21(5):540-544
2. Center for Disease Control and Prevention: Emerging infectious diseases. Brunini, S et al (2017). High Frequency of Mayaro Virus IgM among Febrile Patients, Central Brazil. Research Letter. Volume 23, Number 6—June
3. Figueiredo ML and Figueiredo LT (2014). Emerging alphaviruses in the Americas: Chikungunya and Mayaro. Rev Soc Bras Med Trop.47(6):677-83
Showing the single result
We hold good stocks of all our antigens to ensure a rapid delivery service worldwide. We like to be in touch with our customers so please drop us a line or give us a call on +44 (0)1865 595230. To place an order, please email firstname.lastname@example.org and for further information including price inquiries, bulk preparations and contract services email: email@example.com.